文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌中度大分割放射治疗的前瞻性研究:结局与毒性

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer.
PubMed 文献 · Adv Radiat Oncol · 2017-12-29

这项前瞻性研究纳入2006年12月至2012年2月间40例局限期前列腺癌患者,接受每日锥形束CT引导、64 Gy/20次的中度大分割放疗。中位随访59个月,1组和2组5年生化控制率分别为100%和94.4%,急性≥2级胃肠道和泌尿生殖系统毒性发生率分别为32.5%和42.5%。作者认为该方案有效、毒性可接受。

要点

  • 40例局限期前列腺癌接受64 Gy/20次中度大分割图像引导放疗,中位随访59个月。
  • 1组和2组5年生化控制率分别为100%和94.4%。
  • 急性≥2级胃肠道毒性和泌尿生殖系统毒性发生率分别为32.5%和42.5%。

核心结论

  • 作者认为中度大分割放疗有效,毒性可接受且生化控制良好,进一步提示采用当代放疗技术可安全有效地提高每日分次剂量。

研究设计与样本

  • 前瞻性试验,2006年12月至2012年2月入组40例局限期前列腺癌患者,中位年龄70岁。
  • 1组为T1-T2b期、Gleason评分2至6或7(3+4)且仅累及1叶、前列腺特异性抗原≤10 ng/mL;2组为≥T2c期、Gleason评分≥7(4+3)、7(3+4)累及两叶或前列腺特异性抗原>10 ng/mL且≤30 ng/mL。
  • 所有患者先行经直肠超声引导下基准标记(Visicoil)置入,再行CT/MRI模拟定位,每日锥形束CT在线校正,处方剂量64 Gy分20次。
  • 主要终点为急性和晚期毒性,次要终点为生化控制。

主要发现

  • 1组22例(55%),2组18例(45%);按美国国家综合癌症网络标准,低危13例(32.5%)、中危26例(65%)、高危1例(2.5%)。
  • 1组和2组5年生化控制率分别为100%和94.4%。
  • 13例(32.5%)发生急性≥2级胃肠道毒性,3例(7.5%)发生急性3级胃肠道毒性。
  • 17例(42.5%)发生急性≥2级泌尿生殖系统毒性,1例(2.5%)发生急性3级排尿困难。
  • 2例(5%)发生晚期≥2级胃肠道毒性,其中1例(2.5%)为4级瘘管需行乙状结肠切除;7例(17.5%)发生晚期≥2级泌尿生殖系统毒性,其中2例(5%)为晚期3级尿频/尿急。

关键数值与推荐

  • 处方剂量为64 Gy分20次。
  • 5年生化控制率1组100%、2组94.4%。
  • 急性≥2级胃肠道毒性13例(32.5%),急性3级胃肠道毒性3例(7.5%)。
  • 急性≥2级泌尿生殖系统毒性17例(42.5%),急性3级排尿困难1例(2.5%)。
  • 晚期≥2级胃肠道毒性2例(5%),其中4级瘘管1例(2.5%);晚期≥2级泌尿生殖系统毒性7例(17.5%),其中晚期3级尿频/尿急2例(5%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study is to report the long-term outcomes and toxicity results of a prospective trial of moderately hypofractionated, image guided radiation therapy (RT) for localized prostate cancer. METHODS AND MATERIALS: Patients were enrolled between December 2006 and February 2012. Patients in group 1 were stage T1-T2b, had a Gleason score (GS) of 2 to 6 or 7 (3 + 4) with only 1 lobe involved, and had prostate-specific antigen levels ≤10 ng/mL. Group 2 patients were stage ≥T2c, had a GS ≥7 (4 + 3), a GS 7 (3 + 4) involving both lobes, or a PSA >10 ng/mL and ≤30 ng/mL. All patients underwent transrectal ultrasound guided fiducial (Visicoil) placement prior to computed tomography/magnetic resonance imaging simulation. Daily cone beam computed tomography with online correction was used. The prescribed dose was 64 Gy in 20 fractions. The primary endpoint was acute and late toxicity. The secondary endpoint was biochemical control. RESULTS: A total of 40 patients with a median age of 70 years were recruited for the study. Twenty-two patients (55%) were in group 1, and 18 patients (45%) were in group 2. Thirteen patients (32.5%) were classified as low, 26 patients (65%) as intermediate, and 1 patient (2.5%) as high risk per the National Comprehensive Cancer Network criteria. The median follow-up time was 59 months. Five-year biochemical control was 100% and 94.4% for groups 1 and 2, respectively. Thirteen patients (32.5%) developed acute gastrointestinal (GI) toxicities grade ≥2 and 3 (7.5%) developed acute grade 3 GI toxicity. A total of 17 patients (42.5%) developed grade ≥2 acute genitourinary toxicities and 1 (2.5%) developed acute grade 3 dysuria. Two patients (5%) developed late GI toxicities grade ≥2. There was 1 case (2.5%) of grade 4 fistula requiring sigmoid resection. Seven patients (17.5%) developed grade ≥2 late genitourinary toxicities; 2 patients (5%) late grade 3 urinary frequency/urgency. CONCLUSIONS: Moderately hypofractionated RT is effective with favorable toxicity and biochemical control, providing further evidence that increasing daily fractional dose can be safely and effectively delivered with contemporary RT techniques.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang WG, Yan D, Ye H, et al. Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer. Adv Radiat Oncol. 2017. PMID: 29904741. doi:10.1016/j.adro.2017.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。